James Haberberger

566 total citations
18 papers, 204 citations indexed

About

James Haberberger is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, James Haberberger has authored 18 papers receiving a total of 204 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in James Haberberger's work include Cancer Immunotherapy and Biomarkers (6 papers), Cancer Genomics and Diagnostics (6 papers) and Acute Myeloid Leukemia Research (2 papers). James Haberberger is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Cancer Genomics and Diagnostics (6 papers) and Acute Myeloid Leukemia Research (2 papers). James Haberberger collaborates with scholars based in United States, Switzerland and Greece. James Haberberger's co-authors include Jeffrey S. Ross, Richard S.P. Huang, Shakti Ramkissoon, Douglas I. Lin, Brian M. Alexander, Eric A. Severson, Julia A. Elvin, Natalie Danziger, Ryon P. Graf and Alexa B. Schrock and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

James Haberberger

15 papers receiving 202 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Haberberger United States 9 119 103 50 39 36 18 204
Melike Özçelik Türkiye 10 95 0.8× 78 0.8× 28 0.6× 56 1.4× 11 0.3× 40 232
Erik Asmus United States 6 100 0.8× 41 0.4× 36 0.7× 39 1.0× 29 0.8× 9 179
Shigeki Tanishima Japan 10 87 0.7× 65 0.6× 90 1.8× 58 1.5× 14 0.4× 20 208
Amanda Goldrick Australia 8 166 1.4× 46 0.4× 28 0.6× 83 2.1× 9 0.3× 11 245
Félix Blanc‐Durand France 11 171 1.4× 89 0.9× 41 0.8× 103 2.6× 15 0.4× 40 303
Thais Maloberti Italy 6 62 0.5× 31 0.3× 38 0.8× 54 1.4× 13 0.4× 40 164
Robin J. Baker United States 6 110 0.9× 121 1.2× 64 1.3× 107 2.7× 61 1.7× 8 330
Sherri Damare United States 2 187 1.6× 69 0.7× 101 2.0× 59 1.5× 82 2.3× 2 292
Jesús Alarcón Spain 7 105 0.9× 56 0.5× 22 0.4× 16 0.4× 22 0.6× 14 210
Nathalie Bonichon-Lamichhane France 8 252 2.1× 81 0.8× 33 0.7× 77 2.0× 14 0.4× 17 363

Countries citing papers authored by James Haberberger

Since Specialization
Citations

This map shows the geographic impact of James Haberberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Haberberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Haberberger more than expected).

Fields of papers citing papers by James Haberberger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Haberberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Haberberger. The network helps show where James Haberberger may publish in the future.

Co-authorship network of co-authors of James Haberberger

This figure shows the co-authorship network connecting the top 25 collaborators of James Haberberger. A scholar is included among the top collaborators of James Haberberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Haberberger. James Haberberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Haberberger, James, Hanna Tukachinsky, Jonathan Keith Killian, et al.. (2025). Clinical Use of Liquid-Based Comprehensive Genomic Profiling in Gastrointestinal Stromal Tumors. Laboratory Investigation. 105(5). 104116–104116. 1 indexed citations
2.
Keller, Rachel B., James Haberberger, Alexa B. Schrock, et al.. (2023). Abstract 305: POLE-specific variant classification strategy is critical for identifying patients who may benefit from immunotherapy. Cancer Research. 83(7_Supplement). 305–305.
3.
Johnson, Steven M., James Haberberger, Jonathan Galeotti, et al.. (2023). Comprehensive genomic profiling reveals molecular subsets of ASXL1 -mutated myeloid neoplasms. Leukemia & lymphoma. 65(2). 209–218. 1 indexed citations
4.
5.
Haberberger, James, Russell W. Madison, Alexa B. Schrock, et al.. (2023). Clinical utility of liquid-based comprehensive genomic profiling (CGP) in gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology. 41(16_suppl). 11541–11541. 1 indexed citations
6.
Severson, Eric A., James Haberberger, Amanda Hemmerich, et al.. (2022). Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition. The Oncologist. 28(1). e26–e35. 9 indexed citations
7.
Graf, Ryon P., Virginia Fisher, Janick Weberpals, et al.. (2022). Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open. 5(3). e225394–e225394. 45 indexed citations
8.
9.
Sharaf, Radwa, Dean C. Pavlick, Garrett M. Frampton, et al.. (2021). FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neuro-Oncology Advances. 3(1). vdab017–vdab017. 4 indexed citations
10.
Huang, Richard S.P., James Haberberger, Karthikeyan Murugesan, et al.. (2021). Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. Modern Pathology. 34(7). 1425–1433. 24 indexed citations
11.
Huang, Richard S.P., James Haberberger, Eric A. Severson, et al.. (2021). Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. The Oncologist. 26(5). 375–382. 9 indexed citations
12.
Johnson, Steven M., Lori Ramkissoon, James Haberberger, et al.. (2021). Comprehensive Genomic Characterization of ASXL1 C.1934dupG (p.G646fs*12) Versus Other ASXL1 mutations in Myeloid Neoplasia. Blood. 138(Supplement 1). 3466–3466.
13.
George, Ben, James Haberberger, Ole Gjoerup, et al.. (2021). Comprehensive genomic profiling (CGP) utilizing cell-free DNA (cfDNA) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 39(3_suppl). 421–421. 2 indexed citations
14.
Moutafi, Myrto, Weiwei Tao, Richard S.P. Huang, et al.. (2021). Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer. Journal for ImmunoTherapy of Cancer. 9(4). e002230–e002230. 41 indexed citations
15.
George, Ben, James Haberberger, Ole Gjoerup, et al.. (2021). Correlation between comprehensive genomic profiling (CGP) utilizing tissue-based testing (T-CGP) and cell-free DNA (cfDNA) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 39(3_suppl). 422–422. 3 indexed citations
16.
Huang, Richard S.P., Shoua Yang, Nicholas Britt, et al.. (2020). Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations. JTO Clinical and Research Reports. 2(2). 100100–100100. 11 indexed citations
17.
Lin, Douglas I., Julie Y. Tse, Jonathan Keith Killian, et al.. (2020). Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin. Gynecologic Oncology Reports. 34. 100652–100652. 22 indexed citations
18.
Huang, Richard S.P., James Haberberger, Ethan Sokol, et al.. (2020). Clinicopathologic, genomic and protein expression characterization of 356ROS1fusion driven solid tumors cases. International Journal of Cancer. 148(7). 1778–1788. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Melike Özçelik Breakdown of academic impact, for papers by Erik Asmus Breakdown of academic impact, for papers by Shigeki Tanishima Breakdown of academic impact, for papers by Amanda Goldrick Breakdown of academic impact, for papers by Félix Blanc‐Durand Breakdown of academic impact, for papers by Thais Maloberti Breakdown of academic impact, for papers by Robin J. Baker Breakdown of academic impact, for papers by Sherri Damare Breakdown of academic impact, for papers by Jesús Alarcón Breakdown of academic impact, for papers by Nathalie Bonichon-Lamichhane
Rankless by CCL
2026